Welcome to UK420

Register now to gain access to all of our features. Once registered and logged in, you will be able to contribute to this site by submitting your own content or replying to existing content. You'll be able to customize your profile, receive reputation points as a reward for submitting content, while also communicating with other members via your own private inbox, plus much more!

This message will be removed once you have signed in.

Search the Community: Showing results for tags 'health'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


  • Welcome to UK420
    • New Members
    • Announcements
  • Cultivation
    • Strain Base
    • Breeders Help Desks
    • Compost and Pots
    • Hydroponics
    • Outdoor Growing
    • Propagation, Cloning and Mother Plants
    • Auto Flowering
    • Growroom Design
    • Problem Solver
    • Harvesting and Processing
    • Grow Diaries
    • Cream Of The Crop
  • Cannabis Culture
    • News, Views and Politics
    • Medicinal Cannabis
    • Smokers Lounge
    • Uk420 Competitions
  • Sponsor Support
    • One Tree Horticulture
    • Vapefiend - The Vaporizer Specialists


  • Community Calendar

Found 67 results

  1. hi Clinical Trial in UK: Cannabis as a Treatment Against Covid Is cannabis going to bring salvation to people who have had Covid for a long time, and long-term symptoms caused by their corona infection? To test this in practice, a clinical trial is now starting in the UK. The Australian medical cannabis company Bod Australia has received permission from the British Medicines & Healthcare Products Regulatory Agency. There have been quite a few scientific studies done on the potential of cannabis as a medicine against the new SARS COV2 virus that has been gripping the world for two years now. Although sometimes promising, up to now these have always been laboratory tests with animals or with human (lung) cells in petri dishes. But now, finally, in England they are going to test cannabis as a treatment in real people! Read more on the subject and find the latest cannabis news with the Hemp.im mobile app. Trial of Australian cannabis medicine for people who have had Covid for a long period The trial is being conducted by the Australians in Britain in collaboration with the organization Drug Science. Specifically, people who continue to suffer from corona for a long time (i.e. even after 8 weeks after infection) – such as symptoms as fatigue, shortness of breath, chest pain, muscle aches, headaches, palpitations, persistent highs, forgetfulness, prolonged loss of the sense of smell – are being treated with the drug MediCabilis® 5 percent. Covid is a vast and global problem Covid now also involves large groups of people. In Britain, for example, there are currently around 1.3 million people suffering from Covid, according to the Office for National Statistics (ONS). One in forty corona patients experience symptoms that last at least three months. As you well know, cannabis is widely prescribed – and much more widely used without an official prescription – for the control of chronic pain, something that is also the case with Covid, of course. But anxiety and insomnia, which many Covid patients experience according to the ONS, are also among the most common conditions for which people use cannabis. Not surprisingly, it is thought that many symptoms caused by Covid may well benefit from treatment with cannabis. SEE ALSO XRApplied’s Augmented Reality Solutions Vital to SMEs as Meta Starts Building the Metaverse Similarities between Covid symptoms and reasons for cannabis use Bod Australia is already looking for 30 patients at least 18 years old who have Long Covid after Clinical Trial Authorization so that the clinical trial can start as soon as possible. Participants will soon be administered the cannabis medicine MediCabilis on a daily basis, over a period of six months. Through a smartphone app, they must provide daily and monthly ratings of symptoms such as breathlessness, fatigue, cognition (attention, concentration, etc.), and pain. The results will determine whether this cannabis medicine is suitable and safe to be included in the Covid treatment package. Lead investigator is Dr Elizabeth Iverson and she says: ‘We are delighted that permission for a clinical trial has been granted so that we can conduct this trial into the potential use of medicinal cannabis products to treat Long Covid. Given the ongoing and global presence of Covid-19 and its long-term effects, a scientific approach towards potential treatment mechanisms associated with the condition (Covid, ed.) is important.’ Professor David Nutt: ‘Exciting step’ The founder of partner Drug Science at the Australian company, is no stranger: Professor David Nutt. Made world famous with his ranking of drugs ranked by harmfulness. Once he lost his job as drug advisor to the British government for saying that horseback riding is more harmful to public health than swallowing xtc. So now the professor is chief scientific officer at Drug Science and thus also involved in the clinical trial of cannabis as a Covid treatment. Nutt: “Long Covid shares symptoms with conditions that medicinal cannabis has already proven to be able to cure. So this new study could be an exciting and important step for patients and for wider understanding regarding this medication. Covid is a problem in many countries, our hope is that this UK study will ensure that patients can be helped worldwide. Cannabis medicine instead of pills The CEO of Bod Australia is also optimistic in nature. Jo Patterson: ‘While there are no (successful) existing treatments for Long Covid, our medicinal cannabis products have been used to treat and relieve a number of the same conditions. We expect this clinical trial to give us great insight into the potential of cannabis to treat Covid, and to put more evidence on the table for the use of cannabis medication rather than other pharmaceuticals.’ __ (Featured image by Excellentcc via Pixabay) DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures. First published in CNNBS, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us. https://born2invest.com/articles/clinical-trial-in-uk-cannabis-as-a-treatment-against-covid/ Bongme
  2. Hi Cannabis compound found to protect ageing brain cells 26th January 2022 A cannabis compound can reportedly protect nerve cells from oxidative damage that could, eventually, result in cell death. Researchers suggest these new findings could play a part in treating age-related neurodegenerative diseases, like Alzheimer’s. In a study published in the journal “Free Radical Biology and Medicine”, researchers found that cannabinol (CBN) can actually protect brain cells from damage and death. Medical Xpress reports that CBN, a non-intoxicating compound that has been found to have some medicinal and therapeutic potential, worked by protecting neurons and, more specifically, mitochondria – often referred to as the cell’s powerhouse. Healthy mitochondria (green); mitochondria showing the effects of oxidative stress (blue); and oxidative stress with CBN (red). Insets show higher magnification of the structure of the mitochondria. Credit: Salk Institute In damaged cells, the researchers say, oxidation causes the mitochondria to curl up “like doughnuts”—a change that has also been seen in ageing cells in the brains of people with Alzheimer’s disease. However, treating these cells with CBN reportedly prevented the mitochondria from curling up and kept them functioning well. Pamela Maher, lead author and a research professor and head of Salk’s Cellular Neurobiology Laboratory, said: “We’ve found that cannabinol protects neurons from oxidative stress and cell death, two of the major contributors to Alzheimer’s. “This discovery could one day lead to the development of new therapeutics for treating this disease and other neurodegenerative disorders, like Parkinson’s disease.” While CBN is created when THC, the cannabis plant’s psychoactive compound, begins to age, researchers found that CBN treatment would not result in patients experiencing a “high” from the medicine. First author Zhibin Liang, a postdoctoral fellow in the Maher lab, added: “CBN is not a controlled substance like THC, the psychotropic compound in cannabis, and evidence has shown that CBN is safe in animals and humans. “And because CBN works independently of cannabinoid receptors, CBN could also work in a wide variety of cells with ample therapeutic potential.” While CBN is less known/popular among researchers and those who use cannabis for medical purposes, some studies have found it to be a powerful antibacterial agent. Others have shown that the compound may also be an effective neuroprotectant and anti-inflammatory. https://canex.co.uk/cannabis-cbn-alzheimer-study/ Bongme
  3. hi Weed can stay in your system for a few days to a few months — here's how to get it out faster Weed can be detected in urine between one to 30 days after your last use. Meanwhile, a saliva or blood test can only detect weed for a few days. The only way to get weed out of your system is to stop using marijuana products. Visit Insider's Health Reference library for more advice. If you use weed and have been asked to take a drug test, you're likely wondering how long it will take for your results to be clean. It turns out there's no absolute answer to how long it takes for weed to leave your system. That's because detection time depends on various factors, including the type of test, frequency of consumption, and last use of cannabis. Here's what to expect based on the test you take and tips to flush weed out of your system faster. How long does weed stay in your system? When determining how long weed will stay in your system, healthcare professionals say it all comes down to frequency and the amount you use. "How much you consume and how often will influence how long cannabis stays in your system, but it can depend on an individual's metabolism as well," says April Hatch, RN, co-founder of Cannabis Care Team, a nurse-founded Cannabis education group. When you smoke, vape, or otherwise ingest weed, THC is broken down into several by-products that are stored in various body parts including body fat, the brain, and the heart. Over time, the byproducts stored in the body are released back into the bloodstream where they're then excreted in urine; but chronic, daily smokers can have a THC build-up that accumulates faster than it can be eliminated. Weed usage can generally be divided into three categories: Infrequent users (less than twice a week) Regular users (several times per week) Chronic users (daily) Marijuana drug tests measure the presence of either THC or THC by-products in your bodily fluids or hair, but how long after consumption a test can detect them depends on the specific type of test: 1. Urine test Urine testing is the most common drug testing method. THC byproducts can be detected in urine for the following amounts of time: Infrequent users: One to three days Regular users: Seven to 21 days Chronic users: 30 days or longer. 2. Blood test THC content in blood quickly peaks within the first few minutes of smoking weed and then declines within an hour. But if you consume your weed in edible form, you can expect your blood THC content to peak around 3 hours after consumption. "Blood tests usually detect marijuana for relatively short periods of 1 to 2 days [after last use]," Sternlicht says. However, studies show some frequent marijuana users' blood will test positive even after seven days of abstinence. 3. Saliva test Saliva testing is common in workplaces and uses a swab placed between the lower cheek and gum. Saliva tests can detect marijuana for up to 24 hours after last consumption in infrequent cannabis users, and up to 30 hours in regular and chronic users. 4. Hair Hair follicle testing has the longest detection window, or the period weed can be detected after last use. Hair follicle tests can detect weed for up to 90 days after last consumption, for most users. User frequency Urine test Blood test Saliva test Hair follicle test Infrequent 1-3 days 1-2 days 24 hours 90 days Regular 7-21 days 1-2 days 30 hours 90 days Chronic 30+ days 7 days 30 hou How to get weed out of your system Experts agree the only way to get weed out of your system is to stop using it. And, if you're a chronic smoker, you're likely in for a waiting game. "There are products and lots of anecdotal stories on what will work, but the only way to truly clean out your system is to stop consuming," Hatch says. There are plenty of products on the market claiming they can speed up the weed "detox" process, but these claims are unproven and the products can cause dangerous side effects. Drinking water, eating healthy, or "sweating it out" will not remove weed from your system. Insider's takeaway Patience is the name of the game when it comes to clearing weed out of your system, and regular marijuana users taking urine tests will likely test positive for weeks longer than less frequent users. If you use weed and have to pass a drug test, it's best to stop using right away and give yourself plenty of time to let your body detox. https://www.insider.com/how-long-does-weed-stay-in-your-system Bongme
  4. hi Sugar-free cannabis: Edible makers seek sweet but healthy solutions For much of the past year, the threat of the COVID-19 virus has overshadowed one obvious fact: the major cause of death in America traditionally has been heart disease. According to the Centers for Disease Control and Prevention, some 655,381 U.S. citizens died in 2018 from heart ailments (edging out cancer, which placed second at 599,274). And when it comes to heart problems, many experts in the health field blame refined sugar as a major cause. “(O)ne area that may surprise many men is how their taste for sugar can have a serious impact on their heart health,” said Dr. Frank Hu, professor of nutrition at the Harvard T.H. Chan School of Public Health. Speaking to the Harvard Medical School newsletter, Harvard Health Publishing, he added, “Excess sugar’s impact on obesity and diabetes is well documented.” In a 15-year study, published in 2014, Hu and a team of colleagues discovered that those who consumed between 17 and 21 percent of their calories from added sugar had a 38 percent higher risk of dying from heart disease than those who consumed 8 percent or less. “Basically, the higher the intake of added sugar, the higher the risk for heart disease,” Hu said. Because of such concerns, a number of cannabis producers across the country are offering an array of sugar-free cannabis-infused edibles. In a 2018 story, the cannabis magazine Leafly wrote an article headlined, “12 Sugar-Free Edibles for a Healthier High.” One of the products mentioned was Swifts Edibles Green Tea Peppermint Mints, made by Raymond, Wash.-based Green Labs. Described as “delicious, fresh, and sugar-free,” the mints were said to be, “an all-natural, discreet way to medicate, boasting 20 mints with 100mg THC per container.” Companies across the nation are following suit. One company taking heart health seriously is Wana Brands, a Boulder, Colo.-based maker of edible cannabis products. As the Colorado business newspaper BizWest reported, Wana Brands shifted away from the use of high-fructose corn syrup because of customer demand. The company, CEO Nancy Whiteman said, spent months “searching for the perfect organic sweetener substitute that would not sacrifice our products’ taste and texture.” In Washington, the question of sugar-laden cannabis-infused edibles became an issue in October 2018 when the Washington State Liquor and Cannabis Board banned the sale of many candy-type products. The problem, though, was not the presence of sugar itself but the presumption that cannabis candies would appeal too much to children (the ban was overturned last summer when edible producers agreed to abide by stricter packaging requirements). Whatever the law, the demand for sugar-free cannabis edibles hasn’t gone away, causing Washington producers to continue looking for ways to offer sugar-free alternatives. Jeff Eckenrode, Hashtag Cannabis & Supply Co.’s chief operating officer, wrote that health is one of his company’s top priorities. “(W)hat if you’re trying to lose weight?” Eckenrode asked. “Or if your diet doesn’t allow you to eat foods that are high in sugar? Not to worry, you’re not alone. A lot of the budtenders at Hashtag have dietary restrictions just like you.” Among the products that retailer Hashtag offers at its Seattle and Redmond locations: Olala, which produces a range of sugar-free Sparkling Sodas, and ZootRocks candies that are sweetened with a blend of non-GMO sugar beet and Stevia. Tate Miller, manager of Spokane’s The Vault, says his store carries only one sugar-free brand of edibles at the moment: candies made by the Bellingham-based company Verdelux. He said he’s carried other brands in the past, and he sells a variety of vegan edibles and even some that are kosher. “We try to accommodate everyone we can,” Miller said, adding that the sugar-free edibles he has carried are sought mostly by customers who are diabetic. “There is a demand for it,” he said. “It’s just not as high a demand as for the regular edibles that we carry.” Regardless, he added, when he does have the sugar-free brands on hand, “they go pretty fast.” No wonder. Especially now, you can’t put a price on good health. https://www.spokesman.com/stories/2021/mar/30/sugar-free-cannabis-edible-makers-seek-sweet-but-h/ Bongme
  5. Hi The benefits of cannabis for treating chronic pain Dr Andrew Agius, Medical Director at the Pain Clinic, speaks to HEQ about the benefits of cannabis in treating chronic pain. Cannabis has been used to alleviate acute and chronic pain symptoms for more than 5,000 years, due to its capacity to relieve pain with minimal side effects – particularly in comparison with stronger pharmaceutical painkillers, which can lead to addiction and long-term physical damage. With an increasing number of countries around the world moving to legalise the medical use of cannabis, and consumer demand rising as patients become more aware of the potential benefits of cannabis-based medicines, health, and care centres such as Malta’s Pain Clinic are turning to cannabis to meet the complex pain management needs of vulnerable patients. Dr Andrew Agius, Medical Director at the Pain Clinic, speaks to HEQ about the benefits of cannabis in treating pain. What is the current legal and medical status of cannabis in Malta? Medical cannabis has been legally available in Malta since the law was amended in February 2018. Prior to this, a previous law enacted in 2015 only allowed registered pharmaceutical products such as Sativex to be prescribed; and they could only be prescribed by oncologists, psychiatrists, neurologists, and anaesthetists. Sativex was not available in Malta and all the specialists who were able to prescribe it refused to do so. Patients only began to be able to access medical cannabis when all doctors were permitted to prescribe it, and new products consisting of raw cannabis flowers manufactured under Good Manufacturing Practice (GMP) began to be imported around May 2018. Since then, hundreds of patients have been accessing medical cannabis through a small percentage of doctors, most of whom specialise in family medicine. Most doctors in Malta still refuse to prescribe medical cannabis; and some also advise patients against it. Medical cannabis is mostly prescribed for chronic pain conditions like fibromyalgia where pharmaceutical medication has not been effective or has caused side effects. It is very often prescribed in cases of cancer, where it can help with appetite, pain and the side effects of chemotherapy. It can also be beneficial for other conditions, such as anxiety and insomnia, where many patients are prescribed medical cannabis because it provides relief with fewer side effects than pharmaceutical medication. To access medical cannabis in Malta, a patient needs to be assessed by a doctor who is registered with the Medical Council. Medical cannabis can only be prescribed if the patient has a chronic medical condition for which conventional medication has been prescribed and this medication was not effective or caused debilitating side effects. If the patient is eligible, an application is made to the Superintendent of Public Health, where the doctor declares that they take full responsibility for the patient’s use of the medicine. After due diligence by the Superintendent and a background check to determine whether the patient has attended a drug detoxification programme in the past, patients are approved within two weeks and they are then allowed a 30-day trial of the medicine. If the trial goes well, the doctor can request a six-month approval from the Superintendent. Patients are then able to access medical cannabis from designated pharmacies with a 30-day prescription for narcotic and psychotropic drugs, a control card which is renewed yearly and a permit from the Superintendent which is renewed every six months. If a cannabis user is not registered as a medical patient, the person may be fined between €50 and €100; and they may face more serious charges if they have more than 3.5g in their possession. If a person is caught cultivating one cannabis plant, they may be able to fight it in court on the grounds that it is for personal use; but more than that or any indication that the cannabis may not be solely for personal use could land the cultivator in jail. Another law allowing the production and processing of medical cannabis in Malta, which was adopted later in 2018, will mean that very soon Malta will be importing raw medical cannabis, processing it locally, and then exporting it to the rest of Europe. The prices of medical cannabis products will surely go down as the choice of products increases, and patients will hopefully have easier and more affordable access to their medicine. What benefits does medical cannabis offer in the treatment of chronic pain? Chronic pain is a common disabling condition affecting 20% of the population in Europe, and the incidence of chronic pain is expected to increase following the COVID-19 pandemic. Unfortunately, there are very few pharmaceutical medications which can be used to relieve chronic pain effectively; and these also very often cause side effects which can compound the disability. Recent research shows that the endocannabinoid system is very much involved in the pathophysiology of chronic pain. Patients who develop chronic pain often have a genetic predisposition towards it, which could be related to a dysfunctional endocannabinoid system. Loss of homeostasis and imbalances in neurotransmitter levels often contribute to the symptoms of patients with chronic pain. THC and CBD are two potent therapeutic substances in medical cannabis which can help to rebalance the endocannabinoid system and therefore improve symptoms of chronic pain. Full-spectrum medical cannabis preparations have more than just THC and CBD: they contain more than 140 therapeutic cannabinoids, as well as terpenoids and flavonoids which continue to add to the synergistic effect. This results in a potent therapeutic effect which cannot be wholly explained by the effects of the individual cannabinoids alone, and which is known as the entourage effect. Medical cannabis is highly effective at reducing pain levels, improving mood, reducing anxiety and promoting restful sleep with very few to no unwanted side effects. Patients experience a remarkable improvement in their quality of life and most patients report feeling ‘reborn’ or that they have been ‘allowed another chance to enjoy life’. Medical cannabis literally gives these disabled patients their life back, by helping them manage their symptoms better than anything they would have tried before. In what areas should additional research be conducted to support the role of cannabis in pain management? We know that full-spectrum medical cannabis is much more effective at relieving chronic pain than single-molecule THC or CBD. This is because of the synergistic effect of the cannabinoids with the other therapeutic substances in the plant. Everyone responds differently and some patients respond better than others. We can see the incredible therapeutic potential of this plant, yet there is still so much that we do not know and so much we need to explore. It may take decades before we fully understand the different therapeutic substances in this plant. THC has been extensively studied in chronic pain and we have strong evidence that supports its use. Additional research should investigate the role of CBD, CBG, CBC, CBN and other cannabinoids as treatment in chronic pain, both alone and in combination. Hopefully, the changing laws around the world will allow us better access and make this research easier. What key factors should clinicians bear in mind when prescribing medical cannabis? Medical cannabis is relatively safe compared with pharmaceutical medication, since it has fewer side effects and is better tolerated. However, there are contraindications when prescribing and clinicians should also be aware of possible drug interactions. Since THC may cause psychosis in 1% of the population, clinicians should screen for a possible family history or any symptoms which could indicate an increased risk. Using strains or products with higher levels of CBD and lower levels of THC would reduce the risk of patients developing psychotic side effects, because CBD is an anti-psychotic. Medical cannabis with high levels of THC is also contraindicated in patients who are pregnant or breastfeeding, or who have unstable heart conditions. Since patients respond differently, it is advisable to start with a low dose and tail up very slowly until a therapeutic effect is achieved. Patients are unlikely to experience side effects at these doses. Intoxication can occur with higher doses of THC, but these usually subside within a few hours without any long-term consequences. How do you foresee the medical cannabis landscape in Malta evolving in the next year? As the production of medical cannabis in Malta is projected to start later this year, we are expecting several new products to become available in pharmacies from the various companies that are slowly starting their operations in the next few months. Prices for medical cannabis products should drop dramatically (currently medical cannabis flowers sell for €16 per gram) and we are hoping to see a wide variety of CBD and THC products in various forms and preparations. Malta is expected to become one of the first countries in Europe to produce EU-GMP cannabis medicines which will then be available locally and exported to the rest of Europe. Dr Andrew Agius MD MSc EDPM Medical Director The Pain Clinic www.painclinic.com.mt https://www.healtheuropa.eu/the-benefits-of-cannabis-for-treating-chronic-pain/107099/ Bongme
  6. hi Cannabis may ease lung inflammation from Covid-19, study says Cannabis may help ease and reduce lung inflammation for Covid-19 patients, according to a recent study. Researchers say the non-psychoactive component of cannabis, cannabinol, or CBD, has anti-inflammatory properties. More research should be done on how CBD and treating severe lung inflammation from the coronavirus, according to researchers from University of Nebraska and the Texas Biomedical Research Institute indicates. Their recent peer-reviewed article in the latest issue of Brain, Behavior, and Immunity investigates cannabis’ anti-inflammatory qualities. Covid-19 can cause inflammation that leads to pneumonia which can clog lungs and cause breathing difficulties, an often deadly symptom of the coronavirus. This is why researchers are emphasizing anti-inflammatory treatments for infected patients. There are drug treatments like Tocilizumab that clears patients’ lungs with a 90% success rate, but the side effects are harsh, including the risk of coronary artery disease and pancreas inflammations. Cannabis may be a key solution since it doesn’t carry such severe negative side effects. The CBD treatment made from cannabis does not carry the same effects of THC or smoking marijuana would, though THC has also been shown to be anti-inflammatory but is with more side effects. Cannabis already carries FDA approval, even being used for children with intractable epilepsy. Aside from anti-inflammatory use, CBD also reduces several factors that contribute to severe Covid-19 cases and also increases proteins that prevent the virus from replicating by activating immune cells. Previous studies with asthmatic animals showed CBD reduced airway inflammation as well as pulmonary fibrosis, which can be an after-effect of Covid-19 damaging and scarring lung tissue causing breathing problems. The cannabis study on lung inflammation shows that doses up to 1500 mg a day were safe for up to 2 weeks. The researchers also noted that as an added bonus CBD reduces anxiety, something very useful for the stress of life during a pandemic. Helpfully, cannabis was recently legalized in Thailand and the government has been drafting regulations on importing it. While the article doesn’t directly link cannabis as a treatment for Covid-19, the evidence on CBD’s effect on lung inflammation, a dangerous symptom of coronavirus, makes further research worthwhile. The researchers urge further research to experiment if cannabis can be directly incorporated into Covid-19 treatment to help with inflammation and anxiety too. https://thethaiger.com/coronavirus/cannabis-may-ease-lung-inflammation-from-covid-19-study-says Bongme
  7. hi Link found between cannabis and rebound headaches after migraine People with chronic migraines who use cannabis products are much more likely to suffer from "rebound headaches" than those who don't use the drugs, a preliminary study suggests. However, though a link has been uncovered, it's still unclear whether cannabis directly triggers the rebound headaches, the study authors told Live Science. The study also didn't specify what types of cannabis products the patients used, so it's unknown whether certain products show a greater correlation to rebound headaches than others. A rebound headache, also known as a medication-overuse headache (MOH), happens when a person who already has a headache disorder, such as chronic migraine, either develops a new kind of headache or their existing headaches significantly worsen over time because they are taking headache medication too frequently, according to the International Classification of Headache Disorders (ICHD 3). A formal diagnosis of rebound headaches means that a person has regularly overused one or more drugs to treat their headaches for more than three months. That usually means taking pain-relieving or antimigraine medications more than two or three days a week, according to Harvard Health. In addition, a diagnosed person will have experienced headaches on 15 or more days each month. The rebound headaches usually resolve if patients stop overusing the medications. These headaches affect about 1% to 3% of people in the general population and nearly one-third of the patients who seek treatment for headaches at specialized clinics, such as the Stanford Headache Center, study author Dr. Niushen Zhang, a clinical assistant professor and director of the Headache Fellowship Program at Stanford University School of Medicine, told Live Science in an email. Now, in their new study, Zhang and her colleagues found that people with chronic migraines appear six times more likely to experience rebound headaches if they use cannabis, as compared with migraine patients who don't use the drug. The scientists will present the unpublished research at the American Academy of Neurology's 73rd Annual Meeting, to be held virtually in April. "This study shows that there is some kind of association between cannabis use and medication-overuse headache in people with chronic migraine," Zhang said. However, the research is still in its early days, and "it is unclear at this time whether patients are using cannabis to treat medication-overuse headache or if cannabis is contributing to the development [of] medication-overuse headache, or both," Zhang said. Future studies will be needed to determine whether cannabis contributes to the emergence of rebound headaches, and if so, what that means for those with chronic migraines, she said. For now, "it is too early to provide any clinical recommendations based on the current findings," Zhang added. Zhang and her colleagues launched their study after noticing that a number of their patients with both chronic migraines and MOH also used cannabis products, she said. As there is very little research on cannabis use and these headache disorders, the team decided to explore the association further. "Our study is the first of its kind to assess the risk of medication-overuse headache in chronic migraine patients who use cannabis," Zhang said. The team pulled data from the Stanford Research Repository Cohort Discovery Tool, collecting information on chronic migraine patients treated between 2015 and 2019. They included 368 adults who had experienced chronic migraine for at least a year; 150 reported using cannabis products, and 218 did not use any. The team then assessed which patients had been diagnosed with MOH, taking other variables into account, such as how often they got migraines, how long they'd been using cannabis, when they got diagnosed with MOH and what other medications they took for headaches. They found that 212 patients had MOH, and that patients who reported cannabis use were far more likely to be diagnosed with the disorder. There was also a significant link between cannabis use, opioid use and rebound headaches, they found. "Some of the patients in the study who were using cannabis were also taking, or had a history of taking, opioids," Zhang said. Again, future studies will need to investigate if and how these drugs raise the risk of rebound headaches, as well as what happens when people take them simultaneously. The cannabinoids in cannabis products bind to receptors in the body that regulate the perception of pain, and there is evidence that cannabis products can help alleviate certain types of chronic pain, Live Science previously reported. That said, since this new study reveals a potential link between the drugs and rebound headaches, more research will be needed to see whether cannabis sets migraine patients up for worse headaches, Zhang said. Again, for now, it's too early to say for sure. https://www.livescience.com/cannabis-use-rebound-headache-migraines.html Bongme
  8. hi Vid On Link How the Cannabis plant could fight symptoms of COVID-19 EAST LANSING, Mich. — A Michigan State University professor is currently researching compounds in the Cannabis plant that could possibly help symptoms of COVID 19. Norbert Kaminski, Professor of Pharmacology and Toxicology at MSU has been studying molecules in Cannabis since 1990 to understand how they can apply them for therapeutic use. Most recently he’s been working with GB Sciences a Biopharmaceutical company to identify specific compounds in the plant that don’t have psychotropic properties for anti inflammatory properties, and this could lead to a drug that could help with inflamed lungs, which many experience after contracting COVID 19. “In the case of Covid, those individuals that really have serious health problems often have had too strong an immune response, which compromises the function of their lungs. And so the idea here being that using these cannabinoids is to temper how strong that immune responses so you can still get the benefit of fighting, having your immune system fighting the infection. But now do it in such a strong way that it would actually alter your lung function,” says Norbert Kaminski, MSU Professor of Pharmacology and Toxicology. The research is still in the early phases so it may take time before this new drug is released. Kaminski is hopeful this new drug could be used for cancer treatments as well. https://www.fox17online.com/news/local-news/how-the-cannabis-plant-could-fight-symptoms-of-covid-19 Vid Bongme
  9. hi The First Human Study Focusing On Cannabis For PTSD Treatment Has Been Approved The Battle Brothers Foundation has received approval to launch an observational study on the use of medical cannabis to help combat PTSD in veterans. In concert with NiaMedic, an Israeli-American medical data and research company, the study will determine if cannabis treatment will be beneficial in reducing symptoms in patients with treatment-resistant PTSD. The two groups received approval to proceed with the study from the national Independent Review Board (IRB), which is the independent committee that reviews the methods proposed for research to ensure that they are ethical. The study will enroll 60 California veterans with moderate or severe PTSD over the next year. Participants will dose and titrate individually purchased products by their own discretion. They will then be followed for 90 days to evaluate the safety and efficiency of cannabis on their symptoms. Results of the study will be documented and monitored at that time. Participants will be limited to using legally available cannabis products in California’s market and will also be monitored for any adverse effects due to the use of cannabis. ‘The study hypothesis is that cannabis treatment will be beneficial in reducing the PTSD symptoms in patients with treatment-resistant PTSD,’ says Bryan Buckley, founder and president for the Board of Battle Brothers Foundation. “This news could not come at a better time. Every day, 22 veterans are dying due to effects of post traumatic stress from opioid addiction to depression. Through anecdotal experiences, we know that cannabis can alleviate symptoms and provide relief. We appreciate that the IRB recognizes the validity of and the need for this study,” says Buckley. According to the National Institutes of Health, the rate of PTSD among returning service members varies widely across wars and eras. In one major study of 60,000 Iraq and Afghanistan veterans, 13.5% of deployed and non-deployed veterans screened positive for PTSD, while other studies show the rate to be as high as 20% to 30%. As many as 500,000 U.S. troops who served in these wars over the past 13 years have been diagnosed with PTSD. The Battle Brothers Foundation is the nonprofit arm of Helmand Valley Growers Company (HVGC), a cannabis company founded by disabled United States Special Operations veterans that donates 100% of its profits to fund research on the medical use of cannabis for veterans. In 2016, HVGC founders spoke to members of Congress about the viability of medical cannabis as an alternative to the opioids military veterans were prescribed. They were advised to research data working alongside American medical doctors to build a strong case to present to Veteran’s Affairs (VA). After teaming with NiaMedic, they compiled and presented their proprietary research to the IRB in July 2020. https://www.forbes.com/sites/jacquelinebryant/2021/02/28/the-first-human-study-involving-cannabis-for-ptsd-treatment-has-been-approved/?sh=609007f420da Bongme
  10. hi Developments in cannabis-based drug trial for glioblastomas The Brain Tumour Charity responds to trial suggesting cannabis-based drug could be combined with chemotherapy in recurrent glioblastomas An oral spray containing cannabis-derived chemical extracts could be tolerated in combination with chemotherapy in patients with recurrent glioblastoma, and may in future prove to offer life-extension, the results from an early UK clinical trial suggest. In a new phase 1b trial, researchers led by Professor Susan Short at the University of Leeds (pictured) assessed the safety and potential effectiveness of adding cannabis-based drug Sativex to temozolomide, for patients with a newly recurrent glioblastoma (GBM). While the study observed better one-year survival in the group receiving Sativex, the researchers caution that a larger, randomised trial is needed to assess whether adding Sativex to temozolomide could offer additional life-extension. The study also showed that Sativex did not appear to interfere with temozolomide treatment. The findings come as The Brain Tumour Charity has launched an exceptional grant round with a view to funding a phase II/III multi-centre placebo-controlled clinical trial of cannabinoids in the treatment of high-grade gliomas later this year. Sativex – also known as nabiximols – is a complex botanical formulation containing cannabinoids THC and CBD, alongside other components. It is currently licensed and used in treating muscle stiffness and spasms in certain people with multiple sclerosis. In the first part of the study, 6 patients received a personalised regime of Sativex of up to 12 sprays per day, alongside their temozolomide therapy – and the side-effects were recorded and reviewed. The most common side-effects reported were fatigue, headache, vomiting and nausea, which were mostly classed as being mild-moderate in severity. In the second part of the study, 21 patients were randomised to receive either Sativex with temozolomide (12 patients) or placebo with temozolomide (9 patients) for a total duration of 12 months. 10 out of 12 (83.3%) patients receiving Sativex were still alive after one year, compared to 4 out of 9 (44.4%) patients in the placebo arm. However, two patients in the placebo arm died within 40 days of enrolling and the researchers caution that these patients may have been predisposed to a shorter survival due to features of their tumour, which could skew the comparison with the Sativex arm. Sarah Lindsell, CEO at The Brain Tumour Charity, said: “These are really promising findings and we now urgently need to see a larger clinical trial to understand whether adding cannabinoids to chemotherapy could offer precious extra time to live for people living with a glioblastoma. “With so few options available, thousands affected by a glioblastoma in the UK each year are in urgent need of new treatments, and of new hope. It’s fantastic to see that Sativex could be well-tolerated alongside temozolomide, and that this combination is showing promise in potentially improving outcomes. “We know there is significant interest among our community about the potential activity of cannabinoids in helping relieve symptoms and as a treatment, and we need to do all we can to accelerate these answers and to drive progress. “A cure really can’t wait – and we are really excited to be launching an exceptional grant round to fund a major clinical trial in the UK later this year to fully understand the potential of cannabinoids. “In the meantime, and beyond, anyone affected by a glioblastoma can speak to us on 0808 800 0004 or by emailing support@thebraintumourcharity.org. If you need someone to talk to or advice on where to get help, we’re here for you.” The study is published in the British Journal of Cancer (BJC). In an accompanying editorial, leading UK experts argue the findings “warrant urgent exploration of the combination of temozolomide and nabiximols in a sufficiently powered larger study” alongside research to identify any biomarkers that could help predict their effectiveness for individuals. The BJC editorial, by Dr Gary Doherty at Cambridge University Hospitals NHS Trust and Dr Bruno de Paula at the University of Cambridge, also cautions against the use of off-label nabiximols or other cannabinoid products in patients with GBM until sufficient high-quality evidence supports their use, particularly given the significant side-effect profile. We would always recommend that any supplements, alternative or complementary treatments that you or your loved one wish to use are discussed with your/their medical team. This is because it may, for example, interact with other medications, such as anti-epileptic medicines, steroids or chemotherapy. https://www.thebraintumourcharity.org/media-centre/news/research-news/cannabis-based-drug-trial-developments-glioblastom/ Bongme
  11. hi Presence of fentanyl in cannabis caused a death on P.E.I., CPHO reports An accidental overdose death on P.E.I. was the result of a cannabis product mixed with fentanyl, methamphetamine, and a synthetic drug called W-18. The province's chief public health office (CPHO) stated that an investigation into the death is ongoing. The provincial coroner reported the death - a female in their 20s - to the CPHO on late Friday, Feb. 26. In a media release, Dr. Heather Morrison said anyone consuming street drugs should take steps to reduce risks, carry naloxone kits and inform others using drugs that naloxone is available. This includes any drug in pill or powdered form and is not limited to opioids, she said. As well, anyone consuming cannabis should ensure it comes from a safe source. Fentanyl is a powerful opioid that is 50 to 100 times stronger than morphine and has caused accidental overdoses and death in individuals who consume street drugs. W-18 is an illegal drug similar to carfentanil that is reported to be as much as 10,000 times more powerful than morphine. There were 17 accidental opioid-related overdoses on P.E.I. in 2020 - nine of which involved fentanyl. To date, there have been six opioid-related deaths identified in 2020, three of which involved fentanyl. If an individual feels that they need a naloxone kit, they can contact the provincial Needle Exchange Program toll-free by calling 1-877-637-0333 or visit a program site. Free kits are also available to clients of mental health and addiction programs and select community groups. More information is available online. Anyone with any information in relation to this matter, or other drug related information, is asked to contact your local RCMP detachment or Crime Stoppers at 1-800-222-TIPS (8477). https://www.journalpioneer.com/news/local/cannabis-mixed-with-fentanyl-other-drugs-caused-a-death-on-pei-cpho-reports-557539/ Bongme
  12. hi More Than Half of Cannabis Users With Parkinson’s Disease Report Clinical Benefits A survey in Germany found over 8% of patients with Parkinson’s disease are using cannabis products and more than half experienced beneficial clinical effects, reports the Journal of Parkinson’s Disease. With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson’s disease (PD). According to results of a survey of PD patients in Germany in the Journal of Parkinson’s Disease, over 8% of patients with PD reported using cannabis products and more than half of those users (54%) reported a beneficial clinical effect. Cannabis products containing THC (tetrahydrocannabinol, the main psychoactive compound of cannabis) can be prescribed in Germany when previous therapies are unsuccessful or not tolerated, and where cannabis can be expected with not a very unlikely chance to relieve disabling symptoms. CBD (pure cannabidiol, derived directly from the hemp plant, a cousin of the marijuana plant) is available without a prescription from pharmacies and on the internet. “Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” explained lead investigator Prof. Dr. med. Carsten Buhmann, Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. “PD patients fulfilling these criteria are entitled to be prescribed medical cannabis, but there are few data about which type of cannabinoid and which route of administration might be promising for which PD patient and which symptoms. We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result.” Investigators aimed to assess patient perceptions of medicinal cannabis as well as evaluate the experiences of patients already using cannabis products. They performed a nationwide, cross-sectional, questionnaire-based survey among members of the German Parkinson Association (Deutsche Parkinson Vereinigung e.V.), which is the largest consortium of PD patients in German-speaking countries with nearly 21,000 members. Questionnaires were sent out in April 2019 with the association’s membership journal and were also distributed in the investigators’ clinic. Over 1,300 questionnaires were analyzed; results showed that interest in the PD community in medical cannabis was high, but knowledge about different types of products was limited. Fifty-one percent of respondents were aware of the legality of medicinal cannabis, and 28% were aware of the various routes of administration (inhaling versus oral administration), but only 9% were aware of the difference between THC and CBD. More than 8% of patients were already using cannabinoids and more than half of these users (54%) reported that it had a beneficial clinical effect. The overall tolerability was good. Over 40% of users reported that it helped manage pain and muscle cramps, and more than 20% of users reported a reduction of stiffness (akinesia), freezing, tremor, depression, anxiety, and restless legs. Patients reported that inhaled cannabis products containing THC were more efficient in treating stiffness than oral products containing CBD but were slightly less well tolerated. Patients using cannabis tended to be younger, living in large cities, and more aware of the legal and clinical aspects of medicinal cannabis. Sixty-five percent of non-users were interested in using medicinal cannabis, but lack of knowledge and fear of side effects were reported as main reasons for not trying it. “Our data confirm that PD patients have a high interest in treatment with medicinal cannabis but lacked knowledge about how to take it and especially the differences between the two main cannabinoids, THC and CBD,” noted Prof. Dr. med. Buhmann. “Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. The data reported here may help physicians decide which patients could benefit, which symptoms could be addressed, and which type of cannabinoid and route of administration might be suitable.” “Cannabis intake might be related to a placebo effect because of high patient expectations and conditioning, but even that can be considered as a therapeutic effect. It has to be stressed, though, that our findings are based on subjective patient reports and that clinically appropriate studies are urgently needed,” he concluded. Bastiaan R. Bloem, MD, PhD, Director, Radboudumc Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands, and Co-Editor-in Chief of the Journal of Parkinson’s Disease, added: “These findings are interesting in that they confirm a widespread interest among patients in the use of cannabis as a potential treatment for people living with PD. It is important to emphasize that more research is needed before cannabis can be prescribed as a treatment, and that guidelines currently recommend against the use of cannabis, even as self-medication, because the efficacy is not well established, and because there are safety concerns (adverse effects include among others sedation and hallucinations). As such, the present paper mainly serves to emphasize the need for carefully controlled clinical trials to further establish both the efficacy and safety of cannabis treatment.” Reference: “Cannabis in Parkinson’s Disease: The Patients’ View” by Yenilmez, Ferhat; Fründt, Odette; Hidding, Ute and Buhmann, Carsten, 2 February 2021, Journal of Parkinson’s Disease. DOI: 10.3233/JPD-202260 https://scitechdaily.com/more-than-half-of-cannabis-users-with-parkinsons-disease-report-clinical-benefits/ Bongme
  13. hi Cannabis reduces blood pressure in older adults, according to Ben-Gurion University researchers American Associates, Ben-Gurion University of the Negev Beer-Sheva, Israel...February 8, 2021 - A new discovery by researchers from Ben-Gurion University of the Negev (BGU) and its affiliated Soroka University Medical Center shows that medical cannabis may reduce blood pressure in older adults. The study, published in the European Journal of Internal Medicine, is the first of its kind to focus on the effect of cannabis on blood pressure, heart rate and metabolic parameters in adults 60 and above with hypertension. "Older adults are the fastest growing group of medical cannabis users, yet evidence on cardiovascular safety for this population is scarce," says Dr. Ran Abuhasira of the BGU Faculty of Health Sciences, one of Israel's leading medical faculties, and the BGU-Soroka Cannabis Clinical Research Institute. "This study is part of our ongoing effort to provide clinical research on the actual physiological effects of cannabis over time." Patients were evaluated using 24-hour ambulatory blood pressure monitoring, ECG, blood tests, and body measurements -- both before and three months after initiating cannabis therapy. In the study, researchers found a significant reduction in 24-hour systolic and diastolic blood pressure values, with the lowest point occurring three hours after ingesting cannabis either orally via oil extracts or by smoking. Patients showed reductions in blood pressure in both daytime and nighttime, with more significant changes at night. The BGU researchers theorize that the relief from pain, the indication for prescription cannabis in most patients, may also have contributed to a reduction in blood pressure. "Cannabis research is in its early stages and BGU is at the forefront of evaluating clinical use based on scientific studies," says Doug Seserman, chief executive officer of American Associates, Ben-Gurion University of the Negev. "This new study is one of several that has been published recently by BGU on the medicinal benefits of cannabis." ### Additional researchers who participated in the study include: Prof. Victor Novack, director of the BGU-Soroka Cannabis Clinical Research Institute and BGU-Soroka Clinical Research Center and Research Authority; Prof. Yosef Haviv, director of the Department of Nephrology at Soroka; Prof. Merav Leiba, Prof. Adi Leiba and Dr. Larisa Ryvo of the Assuta Ashdod Academic Medical Center. About American Associates, Ben-Gurion University of the Negev American Associates, Ben-Gurion University of the Negev (AABGU) plays a vital role in sustaining David Ben-Gurion's vision: creating a world-class institution of education and research in the Israeli desert, nurturing the Negev community and sharing the University's expertise locally and around the globe. Activities include showcasing BGU's academic excellence and cutting-edge research through educational programs, events and informative communications. AABGU's main purpose is to support Ben-Gurion's vision and the university that bears his name by creating a community of Americans committed to improving the world tomorrow from the heart of the Israeli desert today. For more information visit http://www.aabgu.org. https://www.eurekalert.org/pub_releases/2021-02/aabu-crb020521.php Bongme
  14. hi Medicinal cannabis mouthwash could help combat COVID-19 LETHBRIDGE, ALTA. -- Igor and Olga Kovalchuk have spent roughly four years working with cannabis strains from around the world to create new hybrids that demonstrate certain therapeutic properties. With the on-set of the COVID-19 pandemic, the University of Lethbridge biology professors have been exploring how some cannabis extracts can help to combat the virus. They investigated how specific cannabis extracts could be used as additional treatments to help ease some of the symptoms and reduce the spread of the virus They released their as preprints which have since been peer reviewed and published to Aging which is one of the top bio-medical journals. The studies, titled ‘In Search of Preventative Strategies’ and ‘Fighting the Storm’ found that certain cannabis extracts help to prevent the virus from entering a person’s cells and can also help to avoid cytokine storms which can lead to acute respiratory distress syndrome. “Peer review is extremely important,” said Dr. Olga Kovalchuk. “We reproduced our original findings and also proved the impacts of the extracts in the lung tissues. These subsequent studies further substantiated our original results.” When the SARS-CoV-2 virus enters a person’s cells, it targets a specific protein on the surface of the cell called ACE2. Essentially, Dr. Igor Kovalchuk said ACE2 acts as a gateway for the virus. “The virus recognizes this cell as infectable by the presence of the ACE2 receptor,” said Dr. Kovalchuk. “We tested whether the application of several of those [cannabis] extracts to see if they would reduce the number of receptors on the surface of the cell and we identified a dozen or so varieties that reduce the expression of the [ACE2] receptor by up to 80 per cent.” Reducing cell receptors Imagine you have a house with a hundred doors and just outside, there are thousands of people lined up to get in each minute. Reducing the number of receptors of a cell is like closing 80 of those doors, drastically slowing down the time in which people can get into your house. “That’s how pathogens work. Especially viruses. They need to get into your cells in order to replicate and our immune system can target them,” said Dr. Kovalchuk. “If the virus enters more slowly because we have fewer receptors, our system has a lot more time to actually target and eliminate those viruses.” Dr. Kovalchuk adds that SARS CoV-2 typically attacks the lungs, the intestine and the oral cavity. The U of L professors have partnered with American-based Good Pharmaceutical Development Company which, with the scientific data collected by the Kovalchuks, has developed a therapeutic oral rinse to combat the virus. Clinical study underway A clinical study into the efficacy of the oral rinse is currently under way, but the findings thus far have been positive. “We’ve developed a clinical score that details in a numerical way patients’ symptoms at the onset of the study. Things like the presence or absence of fever, the height of the fever, the presence or absence of chest pain, shortness of breath, loss of taste and loss of smell, and we gave them a numerical score based upon the severity.” said the company’s president Dr. Larry Good. “In an interim analysis of our data, we have found a very significant reduction in that score. The average score on enrollment was a four. After 14 days of treatment, the average score was 0.4. So, a pretty remarkable reduction in symptoms.” The company is also tracking the number of days it takes for taste and smell to return. The oral rinse is basically a type of mouthwash that the company says should be vigorously swished around the mouth and then swallowed. Good Pharma is now in discussions with an investment bank and a distribution company in the U.S. If the clinical study proves successful, the mouthwash will be sold in the U.S. over the counter. However, it’s a much more complicated process to gain approval from Health Canada. “Health Canada does not allow natural products with active cannabis ingredients. They only allow to put roots, seeds and stems of the plant into the natural extract and these parts of the plant do not have active ingredients. So, it’s useless to do that,” said Dr. Igor Kovalchuk. To get medicine in Canada, people need to go through either pharma, or get what’s considered a natural product. Anything available to purchase over the counter is considered a natural product. When cannabis was legalized in Canada, Health Canada put new rules surrounding cannabis in place. “This came as a shock to many companies that they specifically said, the only parts of the plant that can go into a natural product, are the only parts of the plant that have no active ingredient. This completely defies the purpose entirely! Why would I develop a natural product that doesn’t have cannabinoids or terpenes?” said Dr. Igor Kovalchuk Either way, as it currently stands, the mouthwash will only be available in the U.S. if the clinical study is successful. Both Dr. Kovalchuk and Dr. Good stressed the importance of how specific these cannabis strains are. They said people should not be simply consuming cannabis thinking it will help fight or ward off COVID-19. Experts also say a successful immunization program is still front and center in battling the spread of the virus and the mouthwash is in no way designed for people experiencing severe COVID-19 symptoms. https://calgary.ctvnews.ca/medicinal-cannabis-mouthwash-could-help-combat-covid-19-1.5294988 Bongme
  15. Hi Patients Report Benefits of Medical Cannabis for Parkinson’s Disease Medical cannabis research is at an all-time high, with many trials yielding promising results for a number of conditions and diseases. Research into medical cannabis use for the treatment of Parkinson’s Disease has been ongoing, with a recent survey showing that patients report cannabis as an effective method to manage symptoms of the condition. The study, which was published in the Journal of Parkinson’s Disease, is believed to be the largest study analysing patient’s views on cannabis therapy for Parkinson’s Disease. Participants were recruited from around Germany using the membership journal of the German Parkinson Association. Medical cannabis as a therapy option for Parkinson’s Disease was approved in Germany in 2017. The medicine may be prescribed to patients with severe symptoms associated with the condition when other treatment options have failed or caused too much discomfort/side effects. What is Parkinson’s Disease? Parkinson’s disease affects certain nerve cells in the brain, causing them to break down or die. The loss of neurons that create Dopamine, is the cause of many of the symptoms of the disease. Symptoms of Parkinson’s can include tremors, stiffness and loss of movement. Other symptoms associated with Parkinson’s may include dementia, fatigue, disturbed sleep, and depression. Studies suggest that the physical manifestations of Parkinson’s are actually the late stages of an evolving multi-system disorder. The National Parkinson’s Foundation suggests that motor symptoms of Parkinson’s (PD) only begin to manifest when the majority of the brain’s dopamine-producing cells are already damaged. Therefore, the earlier PD is diagnosed the higher the chances are of slowing the progression of the disease. The Patient Survey Researchers designed a questionnaire to be distributed via issues of the German Parkinson’s Association’s journal from March 2019. The questionnaire was also distributed to patients who visited their movement disorder outpatient clinic from March 4 to April 21, 2019. A total of 1348 responses were analysed for use in the study. The mean age of all participants was 71.6 years, and the mean disease duration was 11.6 years. Of the respondents, 15% reported being cannabis users. Of the cannabis users, 13.9% recorded regular use, 32.2% were occasional users, and 42.6% had tried it once. Overall, 54% of self-reported cannabis users reported a clinical benefit to medical cannabis use. This was, on average, higher in more frequent users (79%) than in occasional (67%) and one-time users (25%). Furthermore, over half of those who had used cannabis reported that it was more effective than levodopa (Parkinson’s medication) and dopamine agonists at improving symptoms associated with the condition. A further 23% considered medical cannabis to be as effective as alternative treatments. https://canex.co.uk/patients-report-benefits-of-medical-cannabis-for-parkinsons-disease/ Bongme
  16. i Over half of cannabis users with Parkinson's disease report clinical benefits A survey in Germany found over 8% of patients with Parkinson's disease are using cannabis products and more than half experienced beneficial clinical effects, reports the Journal of Parkinson's Disease Amsterdam, NL, January 26, 2021 - With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson's disease (PD). According to results of a survey of PD patients in Germany in the Journal of Parkinson's Disease, over 8% of patients with PD reported using cannabis products and more than half of those users (54%) reported a beneficial clinical effect. Cannabis products containing THC (tetrahydrocannabinol, the main psychoactive compound of cannabis) can be prescribed in Germany when previous therapies are unsuccessful or not tolerated, and where cannabis can be expected with not a very unlikely chance to relieve disabling symptoms. CBD (pure cannabidiol, derived directly from the hemp plant, a cousin of the marijuana plant) is available without a prescription from pharmacies and on the internet. "Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data," explained lead investigator Prof. Dr. med. Carsten Buhmann, Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. "PD patients fulfilling these criteria are entitled to be prescribed medical cannabis, but there are few data about which type of cannabinoid and which route of administration might be promising for which PD patient and which symptoms. We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result." Investigators aimed to assess patient perceptions of medicinal cannabis as well as evaluate the experiences of patients already using cannabis products. They performed a nationwide, cross-sectional, questionnaire-based survey among members of the German Parkinson Association (Deutsche Parkinson Vereinigung e.V.), which is the largest consortium of PD patients in German-speaking countries with nearly 21,000 members. Questionnaires were sent out in April 2019 with the association's membership journal and were also distributed in the investigators' clinic. Over 1,300 questionnaires were analyzed; results showed that interest in the PD community in medical cannabis was high, but knowledge about different types of products was limited. Fifty-one percent of respondents were aware of the legality of medicinal cannabis, and 28% were aware of the various routes of administration (inhaling versus oral administration), but only 9% were aware of the difference between THC and CBD. More than 8% of patients were already using cannabinoids and more than half of these users (54%) reported that it had a beneficial clinical effect. The overall tolerability was good. Over 40% of users reported that it helped manage pain and muscle cramps, and more than 20% of users reported a reduction of stiffness (akinesia), freezing, tremor, depression, anxiety, and restless legs. Patients reported that inhaled cannabis products containing THC were more efficient in treating stiffness than oral products containing CBD but were slightly less well tolerated. Patients using cannabis tended to be younger, living in large cities, and more aware of the legal and clinical aspects of medicinal cannabis. Sixty-five percent of non-users were interested in using medicinal cannabis, but lack of knowledge and fear of side effects were reported as main reasons for not trying it. "Our data confirm that PD patients have a high interest in treatment with medicinal cannabis but lacked knowledge about how to take it and especially the differences between the two main cannabinoids, THC and CBD," noted Prof. Dr. med. Buhmann. "Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. The data reported here may help physicians decide which patients could benefit, which symptoms could be addressed, and which type of cannabinoid and route of administration might be suitable." "Cannabis intake might be related to a placebo effect because of high patient expectations and conditioning, but even that can be considered as a therapeutic effect. It has to be stressed, though, that our findings are based on subjective patient reports and that clinically appropriate studies are urgently needed," he concluded. Bastiaan R. Bloem, MD, PhD, Director, Radboudumc Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands, and Co-Editor-in Chief of the Journal of Parkinson's Disease, added: "These findings are interesting in that they confirm a widespread interest among patients in the use of cannabis as a potential treatment for people living with PD. It is important to emphasize that more research is needed before cannabis can be prescribed as a treatment, and that guidelines currently recommend against the use of cannabis, even as self-medication, because the efficacy is not well established, and because there are safety concerns (adverse effects include among others sedation and hallucinations). As such, the present paper mainly serves to emphasize the need for carefully controlled clinical trials to further establish both the efficacy and safety of cannabis treatment." https://www.eurekalert.org/pub_releases/2021-01/ip-oho012621.php Bongme
  17. hi Cannabis Molecule Kills Gonorrhea, MRSA and C. diff Bacteria Five years ago, Australians who were diagnosed with gonorrhea could take a single antibiotic treatment and rid their body of the sexually transmitted disease. Fast forward a few years and the STD is no longer treatable with one antibiotic, having developed resistance over the years. It’s the same thing that has happened to many other types of bacteria, increasing antibiotic resistance year-over-year and resulting in deadly strains, like MRSA, in which no treatment exists. Now, Australian researchers have taken steps toward a new class of antibiotics for resistant bacteria—the first in more than 60 years. For the first time, Mark Blaskovich and colleagues have shown that synthetic cannabidiol, or CBD, can kill Neisseria gonorrhea, the bacteria responsible for gonorrhea. In their study, published in Communications Biology, the researchers showed CBD was not only effective against gonorrhea, but additional types of Gram-negative and Gram-positive bacteria, as well. CBD showed excellent potency against four Gram-negative bacteria: N. gonorrhea (gonorrhea), Neisseria meningitides (meningitis), Moraxella catarrhalis (airway infections like bronchitis and pneumonia) and Legionella pneumophila (Legionnaires’ disease). Meanwhile, it also showed consistent antimicrobial activity against a diverse range of more than 20 types of Gram-positive bacteria, including multiple strains of MRSA and Clostridium difficile. Consistent with previous studies, CBD was inactive against 20 species of Gram-negative bacteria, including E.coli and Klebsiella pneumoniae. Confocal microscopy revealed that CBD was adept at penetrating and destroying biofilms, which is key to treatment as biofilms help bacteria survive antibiotic treatments. The potential of any new antibiotic must always be weighed against the propensity for resistance to emerge. To get a look at CBD’s resistance frequency levels, Blaskovich and his team at the Centre for Superbug Solutions mimicked a two-week patient treatment in laboratory models to see how fast bacteria mutated. When tested against MRSA and multiple strains of C. acne, CBD showed very little to no induced resistance. “Cannabidiol showed a low tendency to cause resistance in bacteria even when we sped up potential development by increasing concentrations of the antibiotic during treatment,” Blaskovich explained. The research team also discovered that CBD’s chemical analogs were active against tested bacteria. “This is particularly exciting because there have been no new molecular classes of antibiotics for Gram-negative infections discovered and approved since the 1960s, and we can now consider designing new analogs of CBD within improved properties,” said Blaskovich. Overall, the study results indicate CBD is an under-researched class of compounds, with various pathways to explore in the future. "We think that cannabidiol kills bacteria by bursting their outer cell membranes, but we don't know yet exactly how it does that, and need to do further research,” said Blaskovich. Further studies are also needed to ascertain whether there are specific pathways targeted by CBD, and whether CBD can be altered to provide systemic activity. During their study, the team’s evaluation of CBD’s systemic antimicrobial activity in an immunocompromised mouse model proved unsuccessful. But, initial evidence has the scientists hypothesizing that CBD’s physicochemical properties can be modified. “Variations were seen in the structure-activity relationship against MRSA and N. gonorrhoeae, meaning there is potential to develop a N. gonorrhoeae targeting agent that is not only selective over other Gram-negative bacteria, but also over Gram-positive bacteria,” the researchers conclude in their paper. “Narrow spectrum antibiotics are increasingly recognized as an important advancement in antibiotic technology, with the ability to spare the natural microbiome by not killing beneficial commensal bacteria. This could potentially provide a substantial advantage for cannabidiol derivatives over other classes of antimicrobial compounds.” As research continues, Botanix, a clinical stage pharma company, collaborated with the Australian scientists to progress a topical CBD formulation into clinical trials for decolonization of MRSA before surgery. The Phase 2a clinical results are expected early this year. https://www.laboratoryequipment.com/572417-Cannabis-Molecule-Kills-Gonorrhea-MRSA-and-C-diff-Bacteria/ Bongme
  18. Hi Survey: Nearly Ten Percent of Parkinson’s Report Using Cannabis Products for Symptom Management Hamburg, Germany: Nearly one-in-ten patients with Parkinson’s Disease (PD) report using cannabis products to alleviate PD-related symptoms, according to a survey of German patients published in the Journal of Parkinson’s Disease. Medical cannabis products have been approved in Germany since 2017 for the treatment of severe symptoms of PD. A team of investigators affiliated with the University of Hamburg conducted a nationwide survey among members of the German Parkinson Association. Over 1,300 patients responded to the survey. Researchers described the study as the “largest” ever undertaken to assess PD patients’ perceptions regarding the use of cannabis. Just under nine percent of survey respondents acknowledged using products containing either THC or CBD or both to mitigate symptoms of the disease. Over half of the respondents (54 percent) reported clinical benefits due to their consumption of cannabis products. Patients were most likely to report that marijuana-based products relieved pain, depression, stiffness/akinesia, and improved sleep. Respondents were more likely to report benefits from products containing THC than those consisting of CBD only. Authors concluded: “Our study offers insights into the PD community’s perception of MC [medical cannabis] and shows that cannabis is applied in almost ten percent of patients against motor- and non-motor symptoms. Results suggest that MC might be helpful for selected PD patients with insufficient symptom relief despite their usual anti-parkinsonian medication.” Observational trial data has previously reported that cannabis inhalation is associated with improvements in tremor, rigidity, pain, sleep, and bradykinesia (slowness of movement) in patients with Parkinson’s Full text of the study, “Cannabis in Parkinson’s Disease: The patients’ view,” appears in the Journal of Parkinson’s Disease. Additional information on cannabinoids and PD is available from NORML. https://norml.org/news/2020/12/17/survey-nearly-ten-percent-of-parkinsons-report-using-cannabis-products-for-symptom-management/ Bongme
  19. Hi True or false Yes, marijuana can be addictive — how to recognize the signs of cannabis use disorder Of the millions of Americans who consume marijuana for recreational or therapeutic use, most will not develop a dependence or addiction. However, research suggests that up to 30% of those who use marijuana may develop a cannabis use disorder or dependency, meaning they continue to use or depend on marijuana despite negative effects. Here's what you need to know about the medical term for a marijuana addiction — cannabis use disorder — and how to tell if your drug use is becoming a problem. Yes, marijuana can be addictive Cannabis use disorder is defined as "a problematic pattern of cannabis use leading to clinically significant impairment or distress," according to the DSM-5. The Diagnostic and Statistical Manual of Mental Disorders (DSM–5) is used by health professionals to diagnose and classify mental disorders. It says that a person must meet two of the following requirements to be diagnosed with cannabis use disorder: You frequently use cannabis in larger amounts or for more time than you intended You have unsuccessfully tried to cut down on your cannabis use You spend a significant amount of time acquiring or using cannabis You often feel strong desires or cravings to use cannabis Your cannabis use interferes with responsibilities at work, school, or home You continue to use cannabis despite it causing social or interpersonal problems You give up social, occupational, or recreational activities because of cannabis use You use cannabis in situations where it's physically dangerous, such as driving You continue to use cannabis despite having a physical or psychological problem that is likely to have been caused or made worse by the drug You've built a tolerance to cannabis, which means you're increasing the amount you consume to achieve effects You experience withdrawal symptoms when cannabis use is stopped When a person is physically addicted to a drug, they will experience physical or mental withdrawal symptoms when they stop consuming it. Physical dependence occurs when the body builds a tolerance to a drug and requires more of it to achieve a certain effect. "While marijuana may not be as physically addictive as substances such as opioids or alcohol, it can be physically addictive," says Aaron Sternlicht, a licensed mental health counselor who specializes in substance abuse disorders in New York City. In fact, a large 2020 meta-analysis examined cannabis users and found 47% experienced withdrawal symptoms when they stopped using cannabis, like: Irritability Nervousness Aggression Sleep disturbances Headaches Appetite disturbances Signs of marijuana addiction Symptoms of marijuana addiction can be similar to symptoms of other drug addictions, like alcohol or cigarettes. "While all drugs are different, all substance use disorders must meet the same criteria in order to be diagnosed and classified as such," Sternlicht says. Drug addiction symptoms or behaviors generally include: Feeling you have to use the drug regularly — daily or even several times a day Over time, needing more of the drug to get the same effect Spending money on the drug, even though you can't afford it Continuing to use the drug, even though you know it's causing problems in your life or causing you physical or psychological harm Failing in your attempts to stop using the drug "Signs of marijuana addiction include not only the physical effects of marijuana intake — like mood changes, slowing of speech, changes in appetite — but also the behavioral changes associated with addiction like being preoccupied with marijuana, experiencing financial hardship, increasingly withdrawn and secretive behavior, involvement in crime or dangerous situations," says Samantha Miller, PhD, a psychologist specializing in children and adolescents at Dell Medical School at the University of Texas at Austin. Risk factors Researchers estimate 3 in 10 marijuana users will develop a cannabis use disorder. This may be more likely for some people, such as: Adolescents: This group has the highest risk of developing a marijuana dependency. People with mental health conditions. Some research has found that a pre-existing mental illness like anxiety, depression, or ADHD may strongly predict the development of a cannabis use disorder. Genetics: People can also be genetically predisposed to addiction if they have a family history of addiction or mental health disorders. Consuming super potent marijuana with a higher percent of THC — the chemical in marijuana responsible for the "high" feeling — can also lead to increased severity of dependence, according to a 2015 study in the UK. "A greater THC content can produce a greater reaction in the brain, resulting in an increased risk of dependence. Furthermore, individuals who smoke marijuana may be at increased risk of dependence compared to those who eat or drink marijuana because of the rate at which the body absorbs the THC," Sternlicht says. Treatment options If marijuana use is interfering with any aspect of your life, you may want to consider stopping your usage. "Think in terms of physical and mental health, education, career, relationships, obligations, finances, sleep routine, hygiene, and all other such life areas. If you are unable to stop or reduce your marijuana use on your own you may need professional help," Sternlicht says. Cannabis use disorder is commonly treated by psychiatrists, psychologists, licensed mental health counselors, or other licensed therapists. A specific type of psychotherapy called Cognitive Behavioral Therapy (CBT) is a particularly effective treatment for substance abuse disorders. For example, a 2001 study found that participants with cannabis dependence were more likely to report abstinence after either a six-session CBT program or a single-session CBT intervention, when compared to a delayed treatment group. "CBT helps individuals identify triggers for relapse and to evaluate unhealthy thoughts and how they impact one's behavior and reality," Sternlicht says. "Many individuals also find it helpful to attend mutual-help groups for additional support such as Marijuana Anonymous, SMART Recovery, Refuge Recovery, and others." Insider's takeaway Marijuana has always been a deeply controversial drug, and while cannabis can be a therapeutic substance, it also comes with a risk of addiction or dependence. Make sure you are aware of the potential risk if you choose to consume marijuana and reach out to your primary care provider if your cannabis use is negatively affecting your life. https://www.insider.com/is-marijuana-addictive Bongme
  20. Hi The Psychedelic Therapy Company Treating Mental Health The results of last month’s elections really got us excited. It will become one of those pivotal periods in history when we can precisely identify the moment that real change began. We’re talking, of course, about all of the drugs that were legalized and decriminalized in November across the United States. The news that states like Mississippi and South Dakota just legalized weed wasn’t even the biggest jaw-dropper. No doubt the real shocker of the night was the state of Oregon decriminalizing hard drugs like cocaine. That overshadowed the other big move in the Beaver state: The passage of Measure 109 gives legal status to the use of psilocybin, the main manna from heaven in magic mushrooms, for treating mental health. The Age of Psychedelic Therapy is upon us. We made our first trip into the mushrooming psychedelic therapy market earlier this year with a list of companies representing the first wave of guinea pigs pioneers. Aside from Oregon, only five cities have decriminalized psychedelics like mushrooms and peyote. While there is still a healthy amount of regulatory risk in both the cannabis and CBD markets, that’s nothing compared to convincing the government and public to approve powerful drugs for day tripping into the ego for fun and profit. (Never mind that each half of both believe the other already lives in a fantasy world.) The Psychedelic Therapy Market Still, that hasn’t stopped the psychedelic market from rapidly taking shape against a vast backdrop painted in vast shades of grey. How do we know? Because there are already several psychedelic therapy market reports already hot off the presses telling us so. Take the press release on a report from Data Bridge Market Research, which projects the psychedelic drug market to grow at a compound annual growth rate of 16.3% to reach $6.85 billion by 2027. There’s certainly a huge potential market for using psychedelics to treat depression, anxiety, and addiction: About a quarter of all Americans are diagnosably crazy in any given year, according to the National Institute of Mental Health Disorders. Depression accounts for about 9.5% of mental health cases annually. Anxiety disorders, including post-traumatic stress disorder (PTSD), affect 18% of people ages 18- 54 in a given year. You can read through a bunch more stats here on depression and anxiety. As far as addiction: In 2018, more than 20 million people had a substance use disorder, according to a report from the Substance Abuse and Mental Health Services Administration. People are having a particularly hard time coping with COVID-19: A government survey found anxiety had tripled and depression quadrupled compared to a 2019 baseline. Psychedelic Therapy Drugs The days of therapy being all about Dr. Freud and mommy issues are long gone. Mental health has embraced everything from virtual reality to wearables to artificial intelligence, so why not party drugs and shaman spirit food? There’s already one such drug on the market from Johnson & Johnson (JNJ), which received approval last year in both the United States and Europe for a ketamine-like nasal spray for depression. An anesthetic that detaches the user from reality, special K (as ketamine is known on the streets) can cause dream-like states and hallucinations. However, in a controlled setting, ketamine-like drugs, as well as other psychedelics, can help produce almost immediate breakthroughs by disrupting ingrained patterns of thinking that affect depressed, anxious, or addicted brains. Our earlier article on psychedelic therapies for mental health goes deeper into the science. Psychedelic therapy is partly about swapping the most addictive drugs with kinder, gentler alternatives that take you to an alternative reality. Credit: ATAI Life Sciences Other psychedelic therapy drugs include: Psilocybin – The OG of psychedelics, found in more than 100 magic mushroom species around the world. N,N-dimethyltryptamine (DMT) – The active psychoactive substance behind the South American beverage ayahuasca. 3,4-methylenedioxy-methamphetamine (MDMA) – Better known as ecstasy (if you’ve ever done it, you know why), MDMA could be the first psychedelic-like drug to be approved by the FDA to treat PTSD. Arketamine and esketamine – Related to special K, both are being studied as powerful antidepressants. Ibogaine – This natural psychoactive compound comes from the root bark of an African shrub, Tabernanthe iboga, with a focus on treating opioid addiction. Kratom – Another plant-based compound for swapping a less addictive-drug (with the added bonus of also being a stimulant) for opioids. Believe it or not, there’s actually one company that’s technically working on all of the above and more. ATAI Life Sciences Founded in 2018, ATAI Life Sciences is a German biotech startup that acts more like a holding company in that it invests in or acquires businesses developing psychedelic therapies. It has already raised about $200 million, including a $125 million Series C round announced last month. The name most people talk about when it comes to the investors is Peter Thiel, the iconoclast billionaire who co-founded PayPal (PYPL) and big data firm Palantir (PLTR). Thiel has certainly embraced some of the edgier biotech themes like boosting longevity through blood transfusions, so you figure he’s already benefiting from micro-dosing. The other name retail investors should know is Christian Angermayer, co-founder of ATAI Life Sciences, because it’s highly likely he would be the driving force behind the company eventually going public (more on that later). Angermayer’s biggest win to date was a merger of his pharmaceutical company Ribopharma with U.S.-based Alnylam Pharmaceuticals (ALNY), which today sports a $15 billion market cap. So he’s got some bonafides (and a net worth reportedly north of $700 million). In ATAI, Angermayer has rapidly built up a portfolio of about a dozen companies, most specifically developing psychedelic therapies. This guy is so committed to the cause of better mental health through chemistry that he got the molecular structure of psilocybin tattooed on his arm: Strange name for a girlfriend. Credit: Twitter Now, let’s take a quick look at ATAI’s portfolio of companies for Psychedelic Therapy. ATAI Life Sciences Portfolio Credit: ATAI Life Sciences Major Investments No doubt the tattoo is related to London-based Compass Pathways, a publicly traded company focused on synthesizing psilocybin. In 2018, the FDA gave the company’s drug candidate, COMP360, “breakthrough therapy” status for treating clinical depression. ATAI is among the nearly dozen investors, including Thiel’s Founders Fund, who sank more than $116 million in Compass Pathways (CMPS) before it went public on the NASDAQ in September. That raised another $127.5 million with a valuation just south of $600 million. Just three months later, the stock is still riding the 2020 market freak train, with a market cap barely south of $2 billion. Last we heard, Compass was in a phase IIb clinical trial for psilocybin therapy in 216 patients with treatment-resistant depression in 21 sites across Europe and North America. The main goal of the study is – as it always should be when you’re tripping – to figure out the optimal dose. Joint Ventures Bloomberg noted that it certainly got Angermayer a higher net worth after netting about $300 million after the IPO as part of his 22% stake. We actually profiled Compass earlier this year before all that went down, as well as another ATAI-linked company in DemeRx, in our original coverage of psychedelic therapy companies. ATAI is supplying up to $22 million to help finance a joint venture to develop Ibogaine as a treatment for opioid addiction. The current drug pipeline is still in the early clinical testing stages, though ATAI said some of the money from the Series C will support work by DemeRx. Another company that we mentioned briefly in that article is Entheogenix Biosciences, another joint venture involving ATAI and an AI computational drug discovery company called Cyclica. The new company will leverage Cyclica’s AI-enabled computational biophysics platform to generate psychedelic-based drug candidates to treat mental health conditions such as schizophrenia and depression. Acquisitions ATAI acquired New Yawk-based Perception Neuroscience in early 2019 and has earmarked some of those Series C dollars for really kicking off the hard clinical work to prove that arketamine can be a gentler and kinder antidepressant than the current cocktails on the market. So far, it’s shown promise in cheering up depressed mice and rats. Considering the current rat race, maybe arketamine will cure what ails our addled brains, as a Phase 1 clinical trial gets underway. Speaking of cures: ATAI added another New York pre-clinical startup this year when it acquired Kures, which raised about $4.2 million in its brief three-year existence. The company’s CEO is also the chief science officer at ATAI, Dr. Srinivas Raoand, and has both a Ph.D. in neurobiology from Yale Graduate School and an M.D. from Yale School of Medicine. So Kures has that going for it, along with a kratom-derived product, KUR-101, which has begun early clinical trials. Launches ATAI has also launched its own homegrown companies, including Viridia Life Sciences in June. Viridia will focus on developing psychedelic therapies based on DMT, which has the advantage of lasting only about 15 minutes versus the standard six-hour hallucinatory trip from magic mushrooms or LSD. Part of the goal will also be to investigate other ways to administer DMT to patients other than the standard acrid drink in the middle of the South American jungle intravenous delivery form. In conjunction with Viridia, ATAI also launched IntroSpect Digital Therapeutics, a platform for creating various kinds of digital services and products, such as remote patient monitoring and precision medicine strategies for delivering optimal doses and formulations. One early indication of what IntroSpect might get into: The new CEO led the development of an artificial intelligence device at another biotech to help treat Alzheimer’s disease based on biofeedback from the patient. A third launch this summer was the creation of Empath Bio, which will develop psychedelic therapies based on MDMA to treat PTSD, a condition that reportedly affects as many as 13 million people in the United States alone. A phase II clinical trial conducted by the Multidisciplinary Association of Psychedelic Research (MAPS) showed that 56% of participants no longer met the criteria for PTSD two months after the final MDMA-assisted psychotherapy session. Additionally, researchers followed up with 91 participants 12 months later and found that 67% still did not meet PTSD criteria. Other companies in the ATAI fold also include: A partnership with GABA Therapeutics, a Los Angeles startup that raised $15.5 million in a Series A last year to develop a non-psychedelic anti-anxiety medication similar to Xanax but without the side effects. Angermayer is listed as an investor in a Series A for Innoplexus, a German startup that applies machine learning to analytics and other areas of health sciences. ATAI has also invested in Neuronasal, a company developing a non-psychedelic nasal spray treatment for concussions and other brain injuries using a supplement called N–acetylcysteine (NAC). Conclusion Several sources that we consulted for this article have suggested ATAI is thinking about going public next year. Let’s hope that doesn’t come in the form of a special purpose acquisition company (SPAC). Psychedelic therapy is the sort of nascent, high-risk market that would only serve to increase the volatility seen in the roulette wheel-style investing that SPACs seem to specialize in. We’ve seen that pattern emerge in NewSpace companies like Virgin Galactic, a space tourism stock, and Momentus, which is doing last-mile delivery in space. SPACS have also become a magnet in the high-risk electric vehicle market, as exemplified by the Nikola Motor Company and its cars that work only especially well rolling downhill. While it’s easy to dismiss psychedelic therapy because it is a new and risky venture, there’s actually some reason to be bullish. Unlike cannabis or CBD, there’s actually quite a bit of real clinical evidence that shows many of these drugs work as advertised. Even U.S. News reported that investing in psychedelic medicine could turn out to be a better bet than weed in the long run. In part, that’s because psychedelic therapy will remain largely the realm of healthcare, meaning the pharmaceutical industry will control access (and prices) to these drugs. Pure-play disruptive tech stocks are not only hard to find, but investing in them is risky business. That's why we created “The Nanalyze Disruptive Tech Portfolio Report,” which lists 20 disruptive tech stocks we love so much we’ve invested in them ourselves. Find out which tech stocks we love, like, and avoid in this special report, now available for all Nanalyze Premium annual subscribers. https://www.nanalyze.com/2020/12/psychedelic-therapy-company-mental-health/ Bongme
  21. hi How Is Cannabis Beneficial For Good Health? The demand for weed is increasing because it is associated with various benefits related to health. It is found in various forms and has a good impact on the body. Weed has all the essential components that affect the mind and body. It keeps the body energetic to do work and keep peace in mind. It is advisable not to consume above limits, but consuming weed in a small amount is beneficial. The chemical component present in cannabis is CBD that directly impacts the brain, thus reducing depression. It has pain-relieving properties that keep sound health. A person can get the natural weed and buy my weed online, consisting of all the beneficial properties needed for the body. Users can enjoy the various benefits of cannabis that are described below – Helpful in reducing pain – The first fantastic benefit that a person gets from the consumption of weed is a reduction in pain. There are many different compounds, among which the main component are Cannabinoids that provide relief in any of the body pain. There is internal pain in the body because of injury, or it can be the pain of joints or anybody ache that can be easily solved by consuming the weed. The continuous taking of weed helps in healthy bones. Thus helpful after the age of 50 by keeping the person fit. Take care of the lungs – Yes, it is rightly said that weed helps in improving the capacity of the lungs. In comparison to this, the people who are consuming cigarettes are too prone to higher risk, causing harm to the lungs. Weed helps in sound breathing and keeps a person subtle in any of the age. Proper research has been done that tells that cannabis helps strong immunity by keeping the lungs in an excellent condition with no harm. A person can take cannabis from buy my weed online for better health benefits. Maintain body weight –Nowadays, people are more likely to have oily and fast food, resulting in overweight and prone to many diseases. There is a busy, hectic schedule, and people don’t get time for exercise and do not have time to keep good health. But the people who consume weed have proper health. It helps to maintain the right that is the proper balance of the body. It regulates the body insulin with proper management of the calories in the body. In this way, a person keeps the appropriate body weight by eating cannabis. it prevents diabetes – Another role that cannabis does for the body is to impact the body insulin that helps regulate, control, and prevent diabetes in the body. Not only is this, but there are other factors also that are maintained in the body. It helps control the blood pressure, makes the balance in blood sugar, and gives the advantage of proper blood circulation, which keeps the various diseases away from the body. Helpful in fighting with cancer – Consumption of cannabis is helpful in the treatment of the significant disease that is cancer. It kills all the cancer symptoms, and the body does not get affected by such a disease. Not only this, it helps to fight cancer and helpful in the treatment of cancer. The medicines used in the treatment of cancer have various side effects on the body, but cannabis helps control all such harmful effects. Deal with depression – Depression is the most widespread problem arising among youngsters and of all age people. This is not that simple as it looks. It becomes the reason for suicide. A scientist has done the research, and they found that the chemicals present in weed help bring peace to mind. Various mood swings are happening because of anxiety. It is recommended to bring weed from buy my weed online, and that contains essential properties that will reduce and finish anxiety, which will keep a good mood and reduce depression and even can finish. Treatment of broken bones – There are fundamental particles present in weed that helps in the treatment of broken bones. The standard treatment takes time and creates a lot of pain, but weed removes all such problems. Cannabis is recognized as the best treatment to cure the pain of injury and fasten the broken bones’ recovery. It makes the bones strong internally, which will not lead to any weakness and will avoid any future injury on the same bone by making the bone so more challenging. Make the body ready to fight with side effects of hepatitis C The treatment that is done for hepatitis C consists of various side effects on the body. The effects that come in the body are – depression, anxiety, nausea, body ache, mood swings, and so on. This causes a significant problem in the body. But there is nothing to worry about as weed is there. Weed helps remove the side effects of the body by controlling the elements present in the medicinal. It helps in making a proper balance of the nutrients in the body. Safer than alcohol – Another best part of cannabis is that it is way far better than weed. Drinking alcohol in the longer-term can bring a severe problem to the body and the internal organs. A person starts getting tiredness in the body and becomes the habit of drinking alcohol. But it is nothing like that from cannabis. It is just the opposite of weed. It becomes toxic for the body if consumption is carried for many years. Its widely advised to consume for better results. Conclusion As we have seen, the incredible benefits of consuming weed. Doctors also recommend having weed consumption that brings activeness in the body and helps make the skin glow and shine. Buy my weed onlineprovides the natural quality weed that boosts up immunity and brings energy to the body. It helps strengthen the bones that will not create any joint or body pain even in older age. It keeps the person adequate and fit. https://theinscribermag.com/how-is-cannabis-beneficial-for-good-health/ Bongme
  22. hi Does CBD Help With Nausea? Here's What Experts Have to Say Feeling nauseated is one of the ickiest feelings in the world. Upset stomachs, throwing up, digestive issues - I would be happy if I never had to experience those again. If you have nausea caused by side effects of another treatment (like chemotherapy), it can be even worse. People have drastically changed their diets, tried motion-sickness bands and pills, and even experimented with Cannabidiol (CBD) to try to ease their nausea. But does CBD really work for nausea? We spoke with a doctor and a nurse who specialize in cannabis therapy to find out. Does CBD Help With Nausea? Although there's been talk about CBD helping with nausea for years, the experts we spoke to said there is just not enough research in humans to support it. Meredith Fisher-Corn, MD, editor-in-chief of The Answer Page, is a board-certified physician specializing in anesthesiology, perioperative and pain medicine, and she served with distinction at Harvard Medical School. She said that CBD has not proven to be successful in helping with other forms of nausea. "Nausea, whether or not accompanied by vomiting, can be quite debilitating," said Dr. Fisher-Corn. "CBD is a substance produced by the cannabis plant that is being advertised and sold as a treatment for a variety of ailments and conditions, including nausea. Regrettably, at this time, there is no human study that demonstrates that CBD effectively treats nausea." Eloise Theisen, RN, MSN, AGPCNP-BC, an adult geriatric nurse practitioner who specializes in cannabis therapy, faculty member at Pacific College of Health and Science's medical cannabis program, and president of the American Cannabis Nurses Association, agreed that more research is needed to see if CBD is effective in treating nausea. She said there are no double-blind, randomized, controlled studies in humans on CBD and nausea (which is a requirement to prove that it helps). However, Theisen did note that there have been some "preclinical studies to demonstrate that CBDa (cannabidiolic acid) and CBD are effective in a dose-dependent manner when treating nausea." TLDR: At this time, experts agree that CBD has not been effectively proven to treat nausea. We just need more research to know if (and at what dose) CBD can be administered for nausea. Do Other Cannabinoids Help with Nausea? CBD is just one form of cannabinoid - other types may be more effective in treating nausea. For example, THC is the psychoactive component of the cannabis plant, and it has been shown to help with nausea, according to the experts we spoke to. Theisen explained that most of the available research on cannabinoids and nausea has looked at THC. "In the 1980s, dronabinol, a synthetic FDA-approved THC pill, was approved for reducing nausea and vomiting in cancer and HIV/AIDS patients," she said. Dr. Fisher-Corn referenced a 2017 study from the National Academies of Sciences, Engineering and Medicine (NASEM) that concluded there was substantial evidence that THC may be effective as an antinausea drug in the treatment of chemotherapy-induced nausea and vomiting. (Keep in mind that the FDA strongly advises against THC, CBD, and marijuana in any form during pregnancy or while breastfeeding). What Should You Know Before Buying CBD For Nausea? Because CBD is not regulated, product purity and potency can vary widely, according to Theisen. If you do buy it, be sure to research online companies and in-person shops beforehand for legitimacy. "It is important to research the company for transparency and to review the certificate of analysis (COA) to ensure that the product label matches the final tested product." There's just not enough information out there to know if CBD actually helps with nausea or if it's just a placebo effect. In the meantime, you can ask your doctor about using THC to get relief. https://uk.news.yahoo.com/does-cbd-help-nausea-heres-203429563.html Bongme
  23. hi Cannabis use disorder may increase risk of COVID-19 hospitalization Researchers in the United States have conducted a study suggesting that genetic vulnerability to a psychiatric syndrome called cannabis use disorder (CUD) may increase the risk of developing severe coronavirus disease 2019 (COVID-19) that requires hospitalization. Cannabis use disorder (CUD) is a moderately-heritable psychiatric syndrome that is genetically correlated with respiratory disease, says the team. Using genome-wide associated analysis (GWAS) summary statistics, the researchers identified a partial genetic overlap between vulnerability to CUD and susceptibility to COVID-19 that requires hospitalization. Further analysis revealed a genomic association between CUD and COVID-19 hospitalization that remained after accounting for potential confounders such as age, smoking status, cardiometabolic traits, and indicators of socioeconomic status. “Heavy problematic cannabis use may increase chances of hospitalization due to COVID-19 respiratory complications,” write the researchers. The team – from Washington University in St. Louis and the University of Colorado – says, “curbing excessive cannabis use may be an essential strategy in COVID-19 mitigation.” A pre-print version of the paper is available on the medRxiv* server, while the article undergoes peer review. Risk of COVID-19 hospitalization could be linked to behavioral factors Genetic vulnerability to hospitalization following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) – the agent that causes COVID-19 – could be partially linked to comorbid behavioral risk factors, particularly the use of combustible psychoactive substances, say Alexander Hatoum (Washington University School of Medicine) and colleagues. Reports have shown that over the course of the COVID-19 pandemic, laws that would usually prohibit the use of cannabis have increasingly permitted its recreational use. On November 3rd, 2020, people in Arizona, Montana, New Jersey, and South Dakota voted to join eleven other states that have already legalized the recreational use of cannabis. Research has also shown that legalization is associated with the increased use of the substance and that one-fifth of people who have tried cannabis go on to develop cannabis CUD. Hatoum and team say it has already been demonstrated that CUD is moderately heritable (50-60%) and genetically correlated with the risk of developing respiratory disease. “As the heterogeneous presentation of COVID-19 is partially attributable to host genomic background and respiratory symptoms are the primary reason for hospitalization and death, genomic liability to CUD may contribute to severe COVID-19 presentation,” write the researchers. What did the current study involve? The team used GWAS summary statistics on CUD (14,080 cases; 343,726 controls) and COVID-19 hospitalization (6,492 cases; 1,012,809 population controls) to assess whether genetic susceptibility to CUD could plausibly influence the risk of being hospitalized with COVID-19. Using linkage disequilibrium score regression analyses, the researchers found that at least one-third of genetic vulnerability to COVID-19 hospitalization overlapped with genetic susceptibility to CUD. “Genetic causality as a potential mechanism of risk could not be excluded,” say Hatoum and the team. Using a series of genomic structural equation models, the researchers identified an independent genomic association between CUD and COVID-19 hospitalization, following adjustment for a range of potential confounders. These variables included genomic susceptibility to tobacco phenotypes (e.g., cigarettes smoked per day, lifetime cannabis use and smoking cessation); cardiometabolic factors (BMI and fasting glucose); socioeconomic status (educational attainment, Townsend deprivation index) and forced expiratory volume. In addition, latent causal variable analyses provided evidence to support that susceptibility to CUD could be genetically causal for COVID-19 hospitalization. Highly speculative, but plausible, says the team The researchers acknowledge that the use of population controls (individuals who may or may not have had COVID-19) in the GWAS may have impacted the precision of the association estimate. They also acknowledge that the GWAS statistics were mainly generated from samples of genomically-confirmed European ancestry, which may limit the generalizability of the findings to other ancestral populations. Hatoum and colleagues say that, while highly speculative, it is plausible that heavy and problematic cannabis use associated with CUD could increase the risk of severe COVID-19. “As the world prepares for surges in COVID-19, identifying putative risk factors associated with severe presentations may mitigate its worldwide impact,” say the researchers. “In contrast to anecdotal evidence and media reports that cannabis may attenuate COVID-19, these data urge caution in heavy cannabis use during the COVID-19 pandemic,” they conclude. https://www.news-medical.net/news/20201119/Cannabis-use-disorder-may-increase-risk-of-COVID-19-hospitalization.aspx Bongme
  24. hi What are Cannabis Seeds and What Happens if you Eat Them? Cannabis seeds are good for your health! Raw fats, which we eat from seeds, nuts or avocados, do not produce the effect of saturation and obstruction (coronary heart disease) that cooked fats (saturated fats) make. However, on the contrary, these fats lower cholesterol, they clean your arteries and can even help you lose weight. Therefore, they are fats that we must include in our diet if we want to maintain a healthy and balanced diet. In some countries, you will not be able to find them as they are illegal due to their connection with marijuana. In the UK, you can legally buy weed seeds, but you can’t germinate them. How to incorporate cannabis seeds into your diet? Hemp seeds can be consumed in different formats: as whole peeled seeds or in the form of cannabis seeds oil or as hemp milk. Peeled Hemp Seeds: They are sold by many stores in some countries and are found in health and diet stores. Cannabis seed has a very hard shell that is impossible to chew; that is why they are sold already peeled. They can be added as a complement to any meal of the day, from a fruit salad to a more elaborate dish. Hemp oil made from cannabis seeds Cannabis seed oil can be found in some herbalists. Its peculiarity is that it is considered one of the healthiest oils that exist since it is composed of 80% essential fatty acids. It is an excellent source of Omega 3 and Omega 6 that prevents cardiovascular diseases, reduces cholesterol, blood pressure, and helps improve arthritis symptoms. It is used like any oil so that it can be added to salads or any dish. They can also be used in desserts such as raw vegan cookies or cakes. Cannabis seeds’ nutritional information (per 100 g.): 25% Protein. 35% of carbohydrates. 35% Oil (essential fatty acids Omega 3 and Omega 6) 380 Kcal Nutrients in marijuana and cannabis seeds If you want to add cannabis to your daily diet, you should get to know the many nutrients and benefits. Nutrients are compounds that all living things need to function. Our own body generates some of them, and others are provided by food. Food plays a vital role in our existence and survival and, depending on the foods we choose. We will have a good or bad quality of life. Issues such as metabolism and organ health are linked to diet. Eat well to live well! Could, then, marijuana be considered a nutritious food? Cannabis seed and its nutritional value Marijuana and its benefits is a field that is currently being actively studied. While this plant has long been used for its healing properties, scientists are now investigating how it affects the human body. After a century of prohibition in consumption, we are not clear about the exact composition of nutrients in cannabis, however, thanks to the experts, we can refer to it as a superfood (superfood). The term refers to foods that provide a large number of health benefits, thanks to the nutritional density they contain. In other words, they are highly recommended! Interesting fact: Cannabis seed is highly rich in protein, so much so that the equivalent of 100 grams of hemp (cannabis seed) hearts; shelled cannabis seeds; contain 32 grams of protein. More than the egg! Cannabis seeds contain nine amino acids that the human body requires, as it cannot produce them on its own. The same 100 grams contain 49 grams of fat (macronutrient), 8 grams of carbohydrates and 4 grams of fibre, according to the latest studies and analyzes. In the same way, we can find vitamin A, vitamin E, calcium, magnesium, potassium and a host of other elements. How to eat hem and cannabis seeds? The question immediately arises: how can I consume cannabis seeds as food? The stems and roots, as well as the seeds and leaves of cannabis, contain nutrients, but they are not consumed due to the type of texture they have. It isn’t easy to eat. Instead, cannabis seeds and leaves are commonly used as aids in nutrition. The best way to consume cannabis is to sprinkle it raw on our food, for example, in a salad with a rich combination of fruits and vegetables on a bed of lettuce. https://www.chiangraitimes.com/health/what-are-cannabis-seeds-and-what-happens-if-you-eat-them/ Bongme
  25. hi New evidence of cannabis’ benefit in Huntington’s Disease lable evidence indicates that cannabis can improve neurological symptoms associated with Huntington disease (HD), according to the findings of a literature review published in the Journal of Pharmacy & Pharmaceutical Sciences. Researchers urge physicians to consider authorizing it for certain patients suffering from the condition. Huntington’s disease is a rare, genetic disease that causes a progressive breakdown (degeneration) of certain nerve cells within the brain. It has a broad impact on a person’s functional abilities and typically causes a variety of movement, thinking (cognitive) and psychiatric disorders. Symptoms of HD can develop at any time, but they often first appear when people are in their 30s or 40s. When the condition develops at an age before reaching 20 years-old, it’s called juvenile Huntington’s disease. Review of scientific record A team of investigators affiliated with the Saint James School of Medicine in Illinois reviewed 22 studies – including five randomized, placebo-controlled trials – assessing the efficacy of either cannabinoids or herbal cannabis for the alleviation of symptoms of HD and other related movement disorders. Of the studies included for review, authors determined that “the majority [of them] showed statistically significant results favoring the use of medical marijuana, especially for improving motor symptoms and quality of sleep.” Authors concluded that additional clinical trials are warranted, but also recommended that in the interim, “physicians consider prescribing medical marijuana as adjunctive treatment for symptomatic relief to slow the progression or reverse spasms, tremor, spasticity, chorea, dystonia, behavioral, neuropsychiatric and sleep disturbances in patients with Huntington disease.” According to the Mayo Clinic, no FDA-approved medications are currently available to mitigate the physical, mental, and behavioral decline associated with HD. http://theleafonline.com/c/medical-use/2020/11/huntingtons-disease-2020/ Bongme